Source comparison
MOTS-C for Endurance Athletes: Metabolic Mechanisms Comparison
Primary Metabolic Target Mitochondrial biogenesis + AMPK activation in skeletal muscle Glycogen supercompensation in liver and muscle Upregulation of fat oxidation enzymes + ketone body utilization MOTS-C targets upstream signaling (PGC-1α) rather than substra
This comparison does not assign a generated winner or score.
- Primary Metabolic Target
- Mitochondrial biogenesis + AMPK activation in skeletal muscle
- Glycogen supercompensation in liver and muscle
- Upregulation of fat oxidation enzymes + ketone body utilization
- MOTS-C targets upstream signaling (PGC-1α) rather than substrate availability. Complementary to training, not a replacement for periodized fueling
- Time to Effect
- 4–8 weeks for mitochondrial density changes (preclinical data)
- 48–72 hours for glycogen loading
- 3–8 weeks for full keto-adaptation
- MOTS-C requires sustained administration. Not an acute intervention like carb-loading
- Impact on Glycogen Sparing
- Increases fat oxidation at submaximal intensities (rodent models showed 30–40% shift toward lipid metabolism)
- None. Relies entirely on glycogen stores
- High. Can maintain 60–70% VO2 max on fat oxidation alone after adaptation
- Glycogen sparing is indirect with MOTS-C (via AMPK-mediated substrate flexibility) vs direct with ketosis
- Effect on High-Intensity Capacity
- Unclear in humans. AMPK activation may blunt mTOR signaling needed for anaerobic power
- Maximizes anaerobic glycolysis
- Significantly reduces. Ketones cannot fuel efforts above lactate threshold
- No human data on MOTS-C's impact on VO2 max intervals or sprint capacity
- Evidence Quality
- Preclinical rodent models + one small human pilot (n=28, sedentary subjects)
- Decades of RCTs in competitive athletes
- RCTs confirm metabolic adaptation but mixed results on performance outcomes
- MOTS-C has mechanistic plausibility but lacks controlled human performance trials